Stockscreener 앱 받기
0.90
8.62%
0.0714
시간 외 거래:
.91
0.01
+1.11%
Windtree Therapeutics Inc 주식(WINT)의 최신 뉴스
Windtree Therapeutics' $200M BNB Bet: A Bold Move to Bridge Biotech and Blockchain - AInvest
Windtree Therapeutics Announces $200 Million BNB Treasury Strategy - AInvest
Windtree to raise $200M to launch a BNB treasury strategy - TheStreet
Windtree Therapeutics to Acquire BNB Tokens in $60 Million Deal - AInvest
Windtree Therapeutics Plans $60 Million BNB Purchase for Crypto Treasury Strategy - AInvest
Windtree to Invest $200M in BNB treasury, First NASDAQ Firm to Do So - The Crypto Times
Windtree Therapeutics Adopts $200 Million BNB Crypto Treasury Strategy - AInvest
Windtree Therapeutics Launches $200 Million BNB Treasury Strategy - AInvest
Windtree Therapeutics to Raise $60 Million via BNB Treasury Strategy - AInvest
Windtree Therapeutics Secures $200 Million for BNB Crypto Treasury Strategy - AInvest
Windtree Therapeutics enters $60 million deal to launch BNB crypto strategy - Investing.com
Windtree Therapeutics, Inc. Announces $60 Million Securities Purchase Agreement to Launch BNB Crypto Treasury Strategy - Quiver Quantitative
Windtree Therapeutics enters $60 million BNB crypto treasury deal By Investing.com - Investing.com South Africa
Windtree Therapeutics enters $60 million BNB crypto treasury deal - Investing.com
Windtree Makes Historic Move: Secures $60M to Become First NASDAQ-Listed BNB Crypto Player - Stock Titan
Why Windtree Therapeutics Inc. stock attracts strong analyst attentionSteady Profit Stock Forecasts - Newser
What makes Windtree Therapeutics Inc. stock price move sharply200 Percent Profit Outlook - Newser
Windtree Therapeutics (WINT) Soars 13.92% on U.S. Patent Issuance - AInvest
Windtree Therapeutics Explodes 27%—What’s Fueling the Surge? - AInvest
Why WINT Stock is Surging? - StocksToTrade
Windtree Therapeutics Soars 76.71% on Patent Win - AInvest
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Windtree Therapeutics (NASDAQ:WINT) Trading Down 14.1% – Here’s What Happened - Defense World
Windtree Therapeutics Secures U.S. Patent for Istaroxime Heart Failure Treatment - MSN
Windtree Therapeutics Plunges 12.06% Amid High Short Interest - AInvest
Windtree Therapeutics Soars 25.97% on Patent Win - AInvest
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment - MSN
Windtree’s Stock Upsurge: Is Innovation the Key? - StocksToTrade
Windtree Therapeutics Issues Convertible Promissory Notes - TipRanks
Windtree Therapeutics receives U.S. patent for istaroxime heart failure drug - Investing.com
Windtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - Nasdaq
Windtree Therapeutics receives U.S. patent for istaroxime heart failure drug By Investing.com - Investing.com India
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis - The Manila Times
Windtree's Breakthrough Cardiogenic Shock Drug Hits Critical Trial Milestone: What's Next for istaroxime? - Stock Titan
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel - The Manila Times
Windtree Slashes PHEXXI Production Costs by 50%New Manufacturing Deal Could Boost 2026 Revenue - Stock Titan
Windtree Therapeutics CFO Resignation and Leadership Shift - TipRanks
Windtree Therapeutics Receives Nasdaq Deficiency Letter - MSN
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MSN
Warrington’s Windtree Therapeutics Acquires Waste Management Company - MSN
Windtree Therapeutics (WINT) Publishes Promising Phase 2 Study R - GuruFocus
Ratios Revealed: Decoding Windtree Therapeutics Inc (WINT)’s Financial Health - DWinneX
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | WINT Stock News - GuruFocus
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study - Yahoo Finance
Breakthrough Heart Treatment: Istaroxime Phase 2 Trial Hits All Endpoints for $1.25B Cardiogenic Shock Market - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May - Defense World
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Titan Environmental to be acquired by Windtree Therapeutics - Investing.com Nigeria
Titan Environmental to be acquired by Windtree Therapeutics By Investing.com - Investing.com South Africa
Windtree Therapeutics Stock Is Volatile This Week: What's Going On? - Benzinga
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics receives $7M offer for oncology platform By Investing.com - Investing.com South Africa
Windtree Therapeutics Raises $3.9M Through Note Agreements - TipRanks
Windtree Therapeutics (WINT) Receives Offer for Oncology Platfor - GuruFocus
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate - The Manila Times
Windtree Therapeutics (WINT) Receives Offer for Oncology Platform | WINT Stock News - GuruFocus
Windtree Therapeutics receives offer for preclinical oncology drug candidate - TipRanks
3.40%
2.49%
자본화:
|
볼륨(24시간):